{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:54:45Z","timestamp":1790895285364,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC22024308"],"award-info":[{"award-number":["SHDC22024308"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Thymic epithelial tumors (TETs) are heterogeneous neoplasms. While most early-stage cases are curable after resection, advanced or aggressive subtypes have limited treatment options and poor outcomes. The molecular mechanisms underlying their metabolic reprogramming remain poorly understood. Proline-rich Coiled-coil 2a (PRRC2A), a N6-methyladenosine (m\n                    <jats:sup>6<\/jats:sup>\n                    A) reader protein, is significantly upregulated in TET tissues and is associated with poor clinical outcomes. Multi-omics analyses and molecular experiments revealed that PRRC2A binds to m\n                    <jats:sup>6<\/jats:sup>\n                    A-modified sites within the NCOA4 mRNA, thereby stabilizing NCOA4 transcripts and enhancing its protein expression. Elevated NCOA4 interacts with PKM2, a rate-limiting glycolytic enzyme, resulting in increased glycolysis and promoting TETs progression. In vivo experiments showed that inhibition of PRRC2A suppressed tumor growth and metastasis in TETs, while combined treatment with the PKM2 inhibitor C599 and PRRC2A knockdown produced enhanced antitumor effects. These findings provide novel insights into the glycolytic metabolic regulation of TETs and suggest that the PRRC2A-NCOA4-PKM2 axis represents a promising therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08883-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:16:57Z","timestamp":1783531017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PRRC2A-mediated m6A modification on NCOA4 promotes thymic epithelial tumor progression through PKM2-induced glycolysis"],"prefix":"10.1038","volume":"17","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-3110","authenticated-orcid":false,"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-5171","authenticated-orcid":false,"given":"Deping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"8883_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8883_CR2","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v40\u201355.","journal-title":"Ann Oncol"},{"key":"8883_CR3","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29:2060\u20135.","journal-title":"J Clin Oncol"},{"key":"8883_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","volume":"35","author":"C Proto","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, et al. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol. 2024;35:817\u201326.","journal-title":"Ann Oncol"},{"key":"8883_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","volume":"17","author":"AC Roden","year":"2022","unstructured":"Roden AC, Ahmad U, Cardillo G, Girard N, Jain D, Marom EM, et al. Thymic carcinomas-a concise multidisciplinary update on recent developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. J Thorac Oncol. 2022;17:637\u201350.","journal-title":"J Thorac Oncol"},{"key":"8883_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","volume":"26","author":"T Shukuya","year":"2025","unstructured":"Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al. Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26:331\u201342.","journal-title":"Lancet Oncol"},{"key":"8883_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1097\/JTO.0000000000000363","volume":"9","author":"AM Litvak","year":"2014","unstructured":"Litvak AM, Woo K, Hayes S, Huang J, Rimner A, Sima CS, et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol. 2014;9:1810\u20135.","journal-title":"J Thorac Oncol"},{"key":"8883_CR8","doi-asserted-by":"publisher","first-page":"S1739","DOI":"10.1097\/JTO.0b013e31821ea553","volume":"6","author":"A Toker","year":"2011","unstructured":"Toker A, Sonett J, Zielinski M, Rea F, Tomulescu V, Detterbeck FC. Standard terms, definitions, and policies for minimally invasive resection of thymoma. J Thorac Oncol. 2011;6:S1739\u201342.","journal-title":"J Thorac Oncol"},{"key":"8883_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S1470-2045(22)00558-7","volume":"23","author":"Y Shintani","year":"2022","unstructured":"Shintani Y, Funaki S. New combination therapy for thymic epithelial tumours. Lancet Oncol. 2022;23:1237\u20139.","journal-title":"Lancet Oncol"},{"key":"8883_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1183\/09059180.00007312","volume":"22","author":"N Girard","year":"2013","unstructured":"Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev. 2013;22:75\u201387.","journal-title":"Eur Respir Rev"},{"key":"8883_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21:14.","journal-title":"Mol Cancer"},{"key":"8883_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-019-0805-7","volume":"12","author":"S Ma","year":"2019","unstructured":"Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 2019;12:121.","journal-title":"J Hematol Oncol"},{"key":"8883_CR13","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1093\/nar\/gkab378","volume":"49","author":"S Oerum","year":"2021","unstructured":"Oerum S, Meynier V, Catala M, Tisn\u00e9 C. A comprehensive review of m6A\/m6Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49:7239\u201355.","journal-title":"Nucleic Acids Res"},{"key":"8883_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","volume":"74","author":"H Shi","year":"2019","unstructured":"Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74:640\u201350.","journal-title":"Mol Cell"},{"key":"8883_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01204-7","volume":"19","author":"T Wang","year":"2020","unstructured":"Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19:88.","journal-title":"Mol Cancer"},{"key":"8883_CR16","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1093\/nar\/gkaa347","volume":"48","author":"H Zhang","year":"2020","unstructured":"Zhang H, Shi X, Huang T, Zhao X, Chen W, Gu N, et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48:6251\u201364.","journal-title":"Nucleic Acids Res"},{"key":"8883_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22:91.","journal-title":"Mol Cancer"},{"key":"8883_CR18","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1093\/nar\/gkad135","volume":"51","author":"J Bohlen","year":"2023","unstructured":"Bohlen J, Roiuk M, Neff M, Teleman AA. PRRC2 proteins impact translation initiation by promoting leaky scanning. Nucleic Acids Res. 2023;51:3391\u2013409.","journal-title":"Nucleic Acids Res"},{"key":"8883_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37252-y","volume":"14","author":"X Tan","year":"2023","unstructured":"Tan X, Zheng C, Zhuang Y, Jin P, Wang F. The m6A reader PRRC2A is essential for meiosis I completion during spermatogenesis. Nat Commun. 2023;14:1636.","journal-title":"Nat Commun"},{"key":"8883_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41422-018-0113-8","volume":"29","author":"R Wu","year":"2019","unstructured":"Wu R, Li A, Sun B, Sun JG, Zhang J, Zhang T, et al. A novel m(6)A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res. 2019;29:23\u201341.","journal-title":"Cell Res"},{"key":"8883_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406935","volume":"12","author":"X Wu","year":"2025","unstructured":"Wu X, Wang S, Pan Y, Li M, Song M, Zhang H, et al. m(6)A reader PRRC2A promotes colorectal cancer progression via CK1\u03b5-mediated activation of WNT and YAP signaling pathways. Adv Sci. 2025;12:e2406935.","journal-title":"Adv Sci"},{"key":"8883_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jare.2024.09.027","volume":"74","author":"G Huang","year":"2025","unstructured":"Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J Adv Res. 2025;74:589\u2013607.","journal-title":"J Adv Res"},{"key":"8883_CR23","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1080\/15548627.2023.2170960","volume":"19","author":"H Wu","year":"2023","unstructured":"Wu H, Liu Q, Shan X, Gao W, Chen Q. ATM orchestrates ferritinophagy and ferroptosis by phosphorylating NCOA4. Autophagy. 2023;19:2062\u201377.","journal-title":"Autophagy"},{"key":"8883_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102413","volume":"55","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhou YL, Mao JA, Tang LF, Xu J, Wang ZX, et al. NCOA4-mediated ferritinophagy is involved in ionizing radiation-induced ferroptosis of intestinal epithelial cells. Redox Biol. 2022;55:102413.","journal-title":"Redox Biol"},{"key":"8883_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41388-024-03050-z","volume":"43","author":"J Song","year":"2024","unstructured":"Song J, Zhang J, Shi Y, Gao Q, Chen H, Ding X, et al. Hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma via the USP2-NCOA4 axis. Oncogene. 2024;43:2000\u201314.","journal-title":"Oncogene"},{"key":"8883_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156666","volume":"141","author":"L Han","year":"2025","unstructured":"Han L, Tian X, Yang X, Li T, Wang S, Bao Y, et al. The pathogenesis of hepatocellular carcinoma: ERK\/ULK1\/NCOA4-mediated inhibition of iron autophagy, and Epimedium extract targeted modulation of this pathway to treat hepatocellular carcinoma. Phytomedicine. 2025;141:156666.","journal-title":"Phytomedicine"},{"key":"8883_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jare.2024.04.033","volume":"65","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jia C, Liu W, Zhan W, Chen Y, Lu J, et al. Sodium citrate targeting Ca(2+)\/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer. J Adv Res. 2024;65:89\u2013104.","journal-title":"J Adv Res"},{"key":"8883_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1\u201311.","journal-title":"Drug Resist Updat"},{"key":"8883_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cac2.12158","volume":"41","author":"JZ Wang","year":"2021","unstructured":"Wang JZ, Zhu W, Han J, Yang X, Zhou R, Lu HC, et al. The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun. 2021;41:560\u201375.","journal-title":"Cancer Commun"},{"key":"8883_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02009-8","volume":"23","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ouyang F, Gao A, Zeng T, Li M, Li H, et al. ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent Warburg effect within the hypoxic tumor microenvironment. Mol Cancer. 2024;23:94.","journal-title":"Mol Cancer"},{"key":"8883_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201\u20136.","journal-title":"Nature"},{"key":"8883_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/cac2.12403","volume":"43","author":"P Xia","year":"2023","unstructured":"Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang Y, et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun. 2023;43:338\u201364.","journal-title":"Cancer Commun"},{"key":"8883_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685\u201396.","journal-title":"Cell"},{"key":"8883_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13046-024-03243-0","volume":"43","author":"EH Zhang","year":"2024","unstructured":"Zhang EH, Yang L, Xu Z, Wang L, Guo T, Xia J, et al. SNAI1 promotes epithelial-mesenchymal transition and maintains cancer stem cell-like properties in thymic epithelial tumors through the PIK3R2\/p-EphA2 Axis. J Exp Clin Cancer Res. 2024;43:324.","journal-title":"J Exp Clin Cancer Res"},{"key":"8883_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177\u201386.","journal-title":"Lancet Oncol"},{"key":"8883_CR36","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/j.cllc.2021.07.008","volume":"23","author":"J Remon","year":"2022","unstructured":"Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernab\u00e9 R, et al. PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients. Clin Lung Cancer. 2022;23:e243\u2013e6.","journal-title":"Clin Lung Cancer"},{"key":"8883_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1722023","volume":"9","author":"KH Kim","year":"2020","unstructured":"Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology. 2020;9:1722023.","journal-title":"Oncoimmunology"},{"key":"8883_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M, et al. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer. 2023;180:117\u201324.","journal-title":"Eur J Cancer"},{"key":"8883_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022;21:60.","journal-title":"Mol Cancer"},{"key":"8883_CR40","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.ymthe.2021.12.012","volume":"30","author":"A Xu","year":"2022","unstructured":"Xu A, Zhang J, Zuo L, Yan H, Chen L, Zhao F, et al. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m(6)A-YTHDF2-dependent manner. Mol Ther. 2022;30:1104\u201318.","journal-title":"Mol Ther"},{"key":"8883_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.gastro.2023.04.032","volume":"165","author":"J Zhai","year":"2023","unstructured":"Zhai J, Chen H, Wong CC, Peng Y, Gou H, Zhang J, et al. ALKBH5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy. Gastroenterology. 2023;165:445\u201362.","journal-title":"Gastroenterology"},{"key":"8883_CR42","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","volume":"187","author":"SM Fendt","year":"2024","unstructured":"Fendt SM. 100 years of the Warburg effect: a cancer metabolism endeavor. Cell. 2024;187:3824\u20138.","journal-title":"Cell"},{"key":"8883_CR43","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2009.27.4662","volume":"28","author":"K Kaira","year":"2010","unstructured":"Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746\u201353.","journal-title":"J Clin Oncol"},{"key":"8883_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01159-6","volume":"13","author":"A Iaiza","year":"2021","unstructured":"Iaiza A, Tito C, Ianniello Z, Ganci F, Laquintana V, Gallo E, et al. METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clin Epigenetics. 2021;13:173.","journal-title":"Clin Epigenetics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08883-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:14Z","timestamp":1790892134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08883-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8883"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08883-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Thymic epithelial tumors and paired adjacent normal tissues were obtained from Shanghai Pulmonary Hospital. Four-week-old male wild-type BALB\/c nude mice were purchased from the Animal Laboratory of Shanghai Pulmonary Hospital. All animal procedures were performed in strict compliance with the guidelines approved by the Ethics Committee. The study protocol was reviewed and approved by the Institutional Review Board of Shanghai Pulmonary Hospital (Approval No. K24-567).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"851"}}